IND Update: Gene-Edited CAR Natural Killer Cell...
Jan. 26, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Fate Therapeutics
General information
Main focus: Allogeneic natural killer cell therapies
Company stage: Clinical
Diseases: Acute myleoid leukaemia (AML), B-cell lymphoma (BCL), chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:FATE)
Location: San Diego, CA, USA
Website: https://fatetherapeutics.com/
Pipeline: https://fatetherapeutics.com/pipeline/
Partners: Janssen Pharmaceuticals, Ono Pharma, Inscripta
Fate Therapeutics is a publicly-traded, clinical-stage, biopharmaceutical company mainly focusing on the development of first-in-class cellular immunotherapies. The company applies an in house iPSC and gene-editing platform to develop T- and natural killer cell therapies targeting blood cancers and solid tumours.
